Morgan Stanley Upgrade Lifts Charles River Laboratories Pre-Market; Biopharma Funding Shift Cited
Charles River Laboratories shares gained in pre-market trade after Morgan Stanley upgraded the contract research organization to Overweight from Equalweight and increased its price target to $220 from $185. The broker cites nascent conversion of constrained biopharma funding into request-for-proposals and bookings, and points to portfolio reshaping…